Insmed (NASDAQ:INSM) COO Roger Adsett Sells 1,429 Shares

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 1,429 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $173.33, for a total transaction of $247,688.57. Following the completion of the sale, the chief operating officer owned 110,462 shares in the company, valued at $19,146,378.46. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $358,616.03.
• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $140,406.14.

Insmed Trading Down 3.3%

INSM traded down $5.73 during mid-day trading on Thursday, hitting $170.27. The stock had a trading volume of 2,588,589 shares, compared to its average volume of 2,142,398. The stock’s fifty day simple moving average is $190.79 and its 200-day simple moving average is $151.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The firm has a market capitalization of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. During the same period last year, the firm earned ($1.27) EPS. Insmed’s quarterly revenue was up 52.4% on a year-over-year basis. As a group, research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Institutional Trading of Insmed

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC boosted its position in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. ORG Partners LLC increased its position in shares of Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares during the last quarter. Hilltop National Bank bought a new stake in shares of Insmed during the 2nd quarter worth approximately $28,000. Stone House Investment Management LLC acquired a new stake in shares of Insmed in the 3rd quarter valued at approximately $29,000. Finally, SBI Securities Co. Ltd. boosted its holdings in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the last quarter.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Wall Street Analyst Weigh In

A number of research firms have recently commented on INSM. Wedbush set a $203.00 price target on Insmed in a research report on Thursday, December 18th. Cowen set a $241.00 target price on Insmed in a research note on Thursday, December 18th. The Goldman Sachs Group upped their price target on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a report on Monday, December 15th. Citigroup restated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Finally, Cantor Fitzgerald upped their target price on shares of Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $205.64.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.